ERCC4 and gastric cancer: The high expression of ERCC4 mRNA indicated a worse OS for all GC patients (HR=1.28, 95% CI=1.02–1.6, P=0.035, Figure 7(a)) and for those with intestinal-type GC (HR=1.87, 95% CI=1.26–2.79, P=0.0018, Figure 7(b)), but there was no association between OS for patients with diffuse and mixed-type GC (Figures 7(c) and 7(d)).